Key result
Author reply provides institutional affiliations and financial disclosures for Dr. Hirschl, including board membership with Takeda Pharma, without reporting any clinical findings.
Key points are not available for this paper at this time.
Design
Other
No new clinical data to guide decisions; leaves open all questions on the topic.
Department of Internal Medicine, Landesklinikum Waldviertel Zwettl, Zwettl, Austria Supported, in part, by the Karl Landsteiner Institute of Coronary Artery Disease and Heart Rhythm Disturbances (St. Pölten, Austria). Dr. Hirschl has board membership with Takeda Pharma and has lectured for MSD, Boston Scientific, Menarini Pharma, and AstraZeneca.
No takes yet. Share an insight, caveat, or question.
Michael M. Hirschl (2013) studied this question. Author reply provides institutional affiliations and financial disclosures for Dr. Hirschl, including board membership with Takeda Pharma, without reporting any clinical findings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: